No Pain, No Gain: A Fallacy So Far

Menée dans le cadre de l'essai MA.27 ayant inclus 7 576 patientes atteintes d'un cancer du sein après la ménopause, cette étude évalue l'assocation entre l'observation de symptômes liés à l'anastrozole ou à l'exemestane et la survie sans récidive

Résumé en anglais

The notion that toxicity related to treatment can be a surrogate for treatment efficacy has long been embedded in the psyche of patients. We are frequently confronted with the question of whether the therapy we have recommended is aggressive—not infrequently a path the patient desires, even if it means more adverse events. Oncologists have also often been attracted to this approach to treatment, believing that a bad disease needs to be treated aggressively, and again this often relates to the adverse events that a patient may experience. However, this philosophy has not always proven to be correct...